![ASCO 2022] Ibrance fails to improve survival in 1st-line breast cancer treatment < Pharma < Article - KBR ASCO 2022] Ibrance fails to improve survival in 1st-line breast cancer treatment < Pharma < Article - KBR](https://cdn.koreabiomed.com/news/photo/202206/13831_14394_912.jpg)
ASCO 2022] Ibrance fails to improve survival in 1st-line breast cancer treatment < Pharma < Article - KBR
![Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10549-020-05755-7/MediaObjects/10549_2020_5755_Fig2_HTML.png)
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink
![Effectiveness and safety of Palbociclib as first-line treatment in advanced breast cancer - ILAPHAR | Revista de la OFIL Effectiveness and safety of Palbociclib as first-line treatment in advanced breast cancer - ILAPHAR | Revista de la OFIL](https://www.ilaphar.org/wp-content/uploads/2023/01/Captura-de-pantalla-2023-01-27-a-las-9.46.04.png)
Effectiveness and safety of Palbociclib as first-line treatment in advanced breast cancer - ILAPHAR | Revista de la OFIL
Efficacy and safety of palbociclib and ribociclib in patients with estrogen and/or progesterone receptor positive, HER2 receptor negative metastatic breast cancer in routine clinical practice | PLOS ONE
![Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study - ScienceDirect Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804922001460-gr2.jpg)
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study - ScienceDirect
![Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia - Sun - 2021 - Cancer Medicine - Wiley Online Library Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia - Sun - 2021 - Cancer Medicine - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/90c32a0b-91b9-49e3-a722-aa39d2a23e6a/cam44295-fig-0002-m.jpg)
Real‐world benefit of combination palbociclib and endocrine therapy for metastatic breast cancer and correlation with neutropenia - Sun - 2021 - Cancer Medicine - Wiley Online Library
![Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs10549-020-05755-7/MediaObjects/10549_2020_5755_Fig1_HTML.png)
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink
![IBRANCE (palbociclib) Pharmacological Properties | Pfizer Medical Information - République française IBRANCE (palbociclib) Pharmacological Properties | Pfizer Medical Information - République française](https://www.pfizermedicalinformation.fr/sites/default/files/content_images/kaplan-meier-plot-or-progression-3.png)
IBRANCE (palbociclib) Pharmacological Properties | Pfizer Medical Information - République française
![Palbociclib Plus Fulvestrant Increases Long-Term Survival in Advanced Breast Cancer - Cancer Therapy Advisor Palbociclib Plus Fulvestrant Increases Long-Term Survival in Advanced Breast Cancer - Cancer Therapy Advisor](https://www.cancertherapyadvisor.com/wp-content/uploads/sites/12/2018/12/thinkstockphotos531314800_1107168.jpg)
Palbociclib Plus Fulvestrant Increases Long-Term Survival in Advanced Breast Cancer - Cancer Therapy Advisor
![Frontiers | Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis Frontiers | Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis](https://www.frontiersin.org/files/Articles/865292/fonc-12-865292-HTML-r2/image_m/fonc-12-865292-g001.jpg)
Frontiers | Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis
![Progression-free survival for palbociclib plus letrozole by line of... | Download Scientific Diagram Progression-free survival for palbociclib plus letrozole by line of... | Download Scientific Diagram](https://www.researchgate.net/publication/331905778/figure/fig1/AS:961366919757827@1606219143521/Progression-free-survival-for-palbociclib-plus-letrozole-by-line-of-therapy-The-median.png)
Progression-free survival for palbociclib plus letrozole by line of... | Download Scientific Diagram
![Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice | Breast Cancer Research | Full Text Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice | Breast Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13058-021-01409-8/MediaObjects/13058_2021_1409_Fig1_HTML.png)
Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice | Breast Cancer Research | Full Text
![Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer | npj Breast Cancer Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer | npj Breast Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41523-022-00479-x/MediaObjects/41523_2022_479_Fig5_HTML.png)
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer | npj Breast Cancer
![Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole ... Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole ...](https://www.clinical-breast-cancer.com/cms/asset/819e2bb2-5bde-4325-8e77-ddc7db393a01/gr1.jpg)
Progression-free Survival Outcome Is Independent of Objective Response in Patients With Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer Treated With Palbociclib Plus Letrozole Compared With Letrozole ...
![Combination of palbociclib with adjuvant endocrine therapy for treatment of hormone receptor‑positive and human epidermal growth factor receptor 2‑negative metastatic breast cancer: An experience at two cancer centers in Saudi Arabia Combination of palbociclib with adjuvant endocrine therapy for treatment of hormone receptor‑positive and human epidermal growth factor receptor 2‑negative metastatic breast cancer: An experience at two cancer centers in Saudi Arabia](https://www.spandidos-publications.com/article_images/mco/17/1/mco-17-01-02552-g01.jpg)
Combination of palbociclib with adjuvant endocrine therapy for treatment of hormone receptor‑positive and human epidermal growth factor receptor 2‑negative metastatic breast cancer: An experience at two cancer centers in Saudi Arabia
![Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer - The Breast Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer - The Breast](https://www.thebreastonline.com/cms/asset/b9d13b56-66f9-4010-b486-c65b0b393de7/gr3.jpg)
Palbociclib dose reductions and the effect on clinical outcomes in patients with advanced breast cancer - The Breast
![Current Oncology | Free Full-Text | Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Current Oncology | Free Full-Text | Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health](https://www.mdpi.com/curroncol/curroncol-29-00089/article_deploy/html/images/curroncol-29-00089-g003.png)
Current Oncology | Free Full-Text | Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health
![Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer | npj Breast Cancer Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer | npj Breast Cancer](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fs41523-022-00479-x/MediaObjects/41523_2022_479_Fig1_HTML.png)
Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer | npj Breast Cancer
![Comparative effectiveness of first line palbociclib plus letrozole vs. letrozole alone for hormone-receptor positive metastatic breast cancer in real world clinical practice - BJMO Comparative effectiveness of first line palbociclib plus letrozole vs. letrozole alone for hormone-receptor positive metastatic breast cancer in real world clinical practice - BJMO](https://www.bjmo.be/app/uploads/2022/01/Tekengebied-4@4x.png)